Tuesday 28 December 2010

Canadian Diplomats Receive Lesson in Biofeedback

Wednesday, December 22, 2010


Ambassador to Germany, Dr. Peter Boehm, and the Canadian High Commissioner to Dusseldorf, Leslie Reissner, paid a visit to the Thought Technology Ltd. booth at Medica, where 137,000 visited for 4 days.

The Head of PR, Andy Shaw wrote in his opening release on Medica : "Finally, Canada's most veteran exhibitor at MEDICA, Thought Technology Limited of Montreal, which many consider (and whose clients include a number of major professional soccer and other sport teams) the world's foremost maker of biofeedback devices, is here with six new products."

When Dr. Boehm asked how Biofeedback & Neurofeedback are used, Thought Technology Vice President and co-founder Lawrence Klein could not resist the opportunity to discuss the many uses of his company's instrumentation. He replied, "The Schulich School of Music " at McGill University in Montreal attached our instruments to several of the musicians of the Boston Philharmonic Orchestra, and 50 audience members. They measured heart rate, skin conductance, respiration, muscle tone, etc. and recorded all in Real Time, in order to discover how emotion is conveyed through music. "

"NASA used these same systems to prepare astronauts in Florida, in a capsule 65 feet under water, for three days, to discover how they adapted to the physical demands of the space capsule. "

Thought Technology Ltd. sales are 95% Medical. Its psychophysiology is used in most VA Hospitals in the United States and it has 150 distributors in 55 countries. It has over 80 percent market share in China, where the distributor focuses on applications for school performance problems and rehabilitation.It recently entered into an OEM agreement to integrate their technology onto the Mediwatch pelvic floor platform.

Mr. Klein stated that, "In addition to the medical market, we have a strong presence in professional and elite sports." Thought Technology's equipment has been used by a number of leading Olympic Sport Coaches as well as by several professional sports teams who have set up a mental training center where trainers monitor the brainwaves, and six other physical functions of the players after their workouts, so they can regenerate and prepare their skills, mentally!

If after their visit to Medica, the Ambassador to Germany, Peter Boehm, and the Canadian High Commissioner to Dusseldorf, Leslie Reissner would like to learn more about how people around the world are using biofeedback, they can attend the Biofeedback Foundation of Europe's 15th Annual Conference in Munich in February 22-26, 2011.

Contact: Helen Mavros
mail(at)thoughttechnology(dot)com
www.thoughttechnology.com



Tuesday 14 December 2010

Mediwatch-US GSA Federal Supply Schedule Contract

14 December 2010



Mediwatch USA Inc. Awarded US General Service Administration Federal Supply Schedule Contract



Mediwatch plc ("Mediwatch" or "the Company") (AIM: MDW), the innovative urological diagnostic manufacturing company, announces that its wholly owned subsidiary, Mediwatch USA Inc. has been awarded a multi-year Federal Supply Schedule Contract by the US Government's General Services Administration (GSA). The GSA Federal Supply Schedule Contract will allow Mediwatch USA Inc. the opportunity to tender for contracts with the US Government to provide equipment, supplies and services.


Under the GSA Federal Supply Schedule Contract, Mediwatch USA Inc. will be able to tender for contracts from 15 December 2010 to 15 September 2013. The Federal annual requirement for pelvic floor products and services is estimated to be approximately $34 million. Under this contract Mediwatch will be able to tender for products in this sector.



Philip Stimpson, Chief Executive Officer of Mediwatch commented:

"Mediwatch is proud to have the opportunity to market to the US Government's hospitals and institutions. Moving into the US government sector on a contract basis is a key and integral part of Mediwatch USA Inc.'s planned growth strategy."


Mediwatch will also qualify to contract for various unrestricted, small business opportunities, which are specifically set aside for smaller businesses and offered by the Federal Government for health care equipment, per diem, staffing and services.



Commenting specifically about these opportunities, Philip Stimpson stated:

"Mediwatch USA Inc. is ready to take the lead as a contractor on many of the small business set aside requirements issued by the Department of Defense and the Department of Veterans Affairs' health care systems."




Monday 13 December 2010

December-Music,Film and the odd joke spot

This has been a very very funny series:






Sunday 12 December 2010

NEWS-Week Ending 12th December (Updated-7 Posts)

Active surveillance and intermediate-risk prostate cancer USA-11th December

Consumer education about the value of PSA testing EU-10th December

The management of high- and intermediate-risk prostate cancer in elderly males USA-9th December

How often is a PSA test really needed to identify risk? EU-9th December

Informed choice and the right to appropriate PSA testing UK-8th December

UK National Screening Committee advises against PSA-based screening initiative UK-6th December

Incidence and mortality rates in 37 European countries EU-6th December

UK-Prostate and bladder cancer screening reviews

The decision not to carry out a UK National screening program for prostate cancer was expected but the Prostate Cancer Charity comments were a little surprising and welcome in the light of past negative comments regarding the PSA test.

3rd December 2010

"Prostate cancer and bladder cancer screening reviews completed

The UK NSC has now completed its reviews of screening for prostate cancer and bladder cancer and the decision made at the meeting on 10 November was that screening is not currently recommended for these conditions."




The Prostate Cancer Charity comments on UK National Screening Committee decision against prostate cancer screening
Date: 6 December 2010

The Prostate Cancer Charity comments on the latest announcement by the UK National Screening Committee not to recommend the development of a screening programme for prostate cancer using the PSA blood test.

John Neate, Chief Executive of The Prostate Cancer Charity, explains: “Although this decision is not a surprise, the announcement from the UK National Screening Committee today is extremely disappointing. While the evidence points to the potential risk of over diagnosis and over treatment through large scale PSA testing, we also know that for some men with aggressive prostate cancer, but no symptoms, the PSA test will be the only early indicator of the cancer at a time when effective treatment can be offered. This makes it essential that all eligible men* are made aware of the test and enabled to make a personal choice about whether it is right for them.

“We believe that a critical opportunity to fully address the inequities faced by men seeking access to the PSA test has been missed. We know that 70 per cent of men over 50 are unaware of the test’s existence or their right to request one from their GP. We also know that this roadblock in accessing the test widens even further for those men from less affluent backgrounds. This is a completely unacceptable state of affairs.

“Although we will always seek to work constructively with Government, the status quo cannot continue. It is a regrettable that this announcement has been made in isolation by the UK National Screening Committee and that a key opportunity to reflect on the wider issues surrounding awareness of prostate cancer and the PSA test was not grasped. This could have been a breakthrough moment for Government to give a firm steer on this critical health issue.

“We will ensure that PSA testing for eligible men is not simply returned to the back-burner and will over the coming months be launching a vigorous and constructive campaign to break this impasse.”

ENDS

* All men over 50 or younger men at a higher risk of the disease due to a family history or from African Caribbean background.


Read the full press release

Tuesday 7 December 2010

UK-Urodynamics training standards established

30 November, 2010 By David Devonport

Minimum standards for training and certification in urodynamics have been established nationally by a multidisciplinary working party in the UK.


The standards suggest a modular training structure and establish minimum workloads for individuals and departments, while advocating the need for multidisciplinary teams and regular audits of their work.

Joint statement on minimum standards for urodynamic practice in the UK


Sunday 28 November 2010

Company Spotlight-Revive Clinic (Australia)

Nurse led clinics do appear to be on the increase which with the current global financial situation along with technology improving all the time then it's of no real surprise.

Revive Clinic is an Australian based network of growing (by the sound) Nurse Led Clinics:

Nurse-led clinic may open soon Australia- 8th November 2010

Anyway,I'll let the company tell their own story:

Revive Clinic - Revive Clinic is a new concept designed to give faster, more convenient access to a wide range of affordable basic healthcare and preventative care. Staffed by highly experienced nurse practitioners who are specially trained to diagnose, treat and prescribe for a wide range of minor illnesses, injuries, provide vaccinations, prescriptions, health checks and condition management and monitoring. All services are provided in collaboration with patients GP, pharmacists, allied health or specialists. Revive Clinics are also conveniently located in pharmacies where you shop.






About Revive Clinic

Revive Clinic is a new concept designed to give faster, more convenient access to a wide range of affordable basic healthcare and preventative care.

Staffed by highly experienced nurse practitioners who are specially trained to diagnose, treat and prescribe for a wide range of minor illnesses, injuries, provide vaccinations, prescriptions, health checks and condition management and monitoring. All services are provided in collaboration with patients GP, pharmacists, allied health or specialists.

Our Nurse Practitioners are able to help patients manage their health more effectively, refer for pathology, x-rays and to specialists when required. We are your support network in between visits to your GP or when you GP is unavailable. Patient’s doctors are kept up to date on any treatments provided at a Revive Clinic.

We are also conveniently located in pharmacies where you shop. Stop by anytime. No appointments are necessary.

Medicare rebates available on Revive Clinic services from 1st November 2010. Private health insurance rebates available on selected programs.

What’s a Nurse Practitioner?

Nurse practitioners are registered nurses with advanced education and training in the diagnosis and management of common health conditions. They have the authority to prescribe medication and order diagnostic tests.

Nurse practitioners are focused on disease prevention and treat minor everyday ailments. Recently the Australian Government invested $2.1m in providing scholarships to help boost nurse practitioner numbers nationwide.

As can be seen from Clinic Services page they cover Urinary Tract and Bladder problems along with Prostate Serum Antigen Test (PSA test).Not sure if they are using Mediwatch products but just highlighting the growing possibilities and applications suited to their product range.

Saturday 27 November 2010

Nurse-led-clinics Website

Here is a new (October 2010 by the look) UK based website that is directed to Nurse Led Clinics.



This site is designed and run for qualified (registered) nurses involved in setting up or running their own nurse-led clinics. It offers the chance to explore this form of health care delivery and update on reviews of the latest news and information in this area.

New video clips (scroll down) are added regularly and our message board allows you to request and share information across the world. Remember to use our search box for abstracts of papers related to your own area of practice..

NEW VIDEOS ON THE WAY!

The growth of the Nurse Practitioner in Montreal (end November)
Creating a business plan for your clinic (early December)









Nurse Led Clinics-New Zealand

Not sure if they are using Mediwatch products but it's a field that Mediwatch are aiming for.I will add this to the main page found within the month of April 2009 under NURSE LED CLINICS/MOBILE CLINICS

Published 2010-10-29
Teamwork amongst urology nurses at NZ hospital - Specialised knowledge not size matters in small urology clinic

Greetings to our urological nursing colleagues in the EAUN! With the invitation to write for your newsletter we would like let you know a little of our urological practice here in Hawke’s Bay, New Zealand.

Our hospital is located on the east coast of the NorthIsland and our main industries are agricultural including a booming wine industry! The current population is 150,000 of which 25% are indigenous Maori. The District Health Board employs 2,500 peoplewhich makes it the largest employer in our region. Hawke’s Bay is also served by a private hospital and two of our urologists also work there providing surgery to those that either have insurance or can afford to pay.


From left: Robyn, Trish and Julia

The urology team provides most elective and acute urological services including paediatric surgery. We do not have the funding, or the population base, to make robotic surgery feasible in this area so we refer our patients to the main centres if they chose this treatment option. We also do not have radiotherapy services available locally, but this option is availablein another centre which is two hours away by car. For those opting to have brachytherapy, the procedure is available even farther away after a four-hour drive.

Up until just recently we have had only two urologists, Mr. David Mason and Mr. Kim Broome in our team. But we are happy to announce we have just employeda third urologist, Dr. Leanne Shaw, who recently completed her fellowship year working overseas with Dr. Tony Mundy in London. With Dr Shaw’s interest and expert knowledge in urethral surgery we are very excited to have her working in our team. We also have a trainee registrar in our service.

Currently, we have six members of the New Zealand Urology Nurses Society working in our area. Three of them work in out patient clinics, namely Julia Nelson,Robyn Madden and Goh Yee Tan, and they coordinate six urologist outpatient clinics each week. There are also two nurse practitioner clinics and two urology nurse clinics. In total we see approximately 140 urology outpatients per week. The registered nurses working in the clinics assist the urologists with anumber of procedures including prepping and assisting with cystoscopy, urethral dilatation, TRUS prostate biopsies, stent removal, urodynamics and testosterone implants.

One registered nurse has responsibility for each clinic, planning and preparing a suitable patient mix of new patients, follow ups, procedures and acute patients.This nurse also phones all booked consultant urologyclinic patients prior to their appointment to confirm their attendance. She also checks if tests have been completed and ensures that the patient has received the relevant information, i.e. attending clinic with a full bladder. The clinic nurses have audited this service and found it cuts down significantly on patients missing appointments.
The nurse-led clinics are held twice a week for patients receiving BCG treatment, GnRH and LHRH analogue assessment and administration, urethraldilatations, flow rates and teaching of intermittent selfc atheterisation. The registered nurse role, in all urology clinics, is to support and assist the consultant whilst caring and advocating for the patient.

We were all delighted when last year two of ourmembers, Julia Nelson and Goh Yee Tan were awarded the “OBEX Best Paper” prize at our nationalNZUNS conference. They gave an excellent presentation of their work wherein they developed an orientation package for registered nurses who are new to the Outpatient Department. They used their $2,500 prize to travel to Perth, Australia where they attended the ANZUNS conference in March 2010.

Trish White, our nurse practitioner, has been in herrole for four years now. She sees a mix of new patients and follow-up appointments in clinics as well as offering a case management service for our more complex urological patients which involves community visits. Trish sees a lot of patients with lower urinary tract symptoms, incontinence, recurrent UTI and prostate cancer. She is also keen on research having published the results of her study, which she completed with her colleague, Helen Crowe fromMelbourne, Australia. Their study titled “Definingurology nursing practice roles in Australia and New Zealand” appeared in the International Journal ofUrological Nursing in 2009.

Our operating theatre is managed by Lynn Brinson who also runs the gynaecology theatre. She coordinates five busy sessions per week in herdepartment. Our urology in-patient unit is small with only, on average, eight in-patient beds. We are very proud of Lynn’s recent achievement of becoming one of New Zealand’s First Surgical Assistant which permits her to assist the Urologists in surgery. Athorough assessment by New Zealand Nursing Council is required before a Registered Nurse can work in this extended scope of practice.

While we are a small provincial urology departmentwe foster team work and have regular Friday morning meetings so we can all discuss the coming week’s surgical lists to ensure patients are ready and well as they can be. Everyone is encouraged to contribute during this meeting and it helps our team run smoothly. We are all very keen to participate in national or international meetings so hopefully, one day, we will be able to attend one of your European meetings!

Authors:
Trish White, Nurse Practitioner Adult Urology,
Trish.White@hawkesbaydhb.govt.nz

Julia Nelson, Registered Nurse Outpatient Clinics
Robyn Madden, Registered Nurse Outpatient Clinics
Hawke’s Bay District Health Board, Hawke’s Bay (NZ)

Article from European Urology Today, volume 22, No. 4

Monday 8 November 2010

Pelvic Floor Biofeedback Therapy/Retraining

A little post giving some information relating to Pelvic Floor Biofeedback Therapy/Retraining:

The Mediwatch solutions



(Venus-US only at present time)



And the associated pdf:



What's it all about....


Introduction

Pelvic floor biofeedback therapy is a treatment intended to help patients learn to strengthen and relax their pelvic muscles in order to improve bladder function and decrease pelvic pain. Biofeedback uses electronic and mechanical instruments to accurately measure the action of the pelvic floor muscles, and provides ‘feedback’ information to the patient so that the patient can learn to better use the pelvic muscles. Patients can learn to use the pelvic floor muscles to decrease the sudden urge to urinate, decrease incontinence, and lessen certain types of pelvic pain. An important part of pelvic floor biofeedback therapy is consistent exercise of the pelvic muscles at home, and biofeedback therapy can help teach proper pelvic muscle exercise.

Pelvic floor biofeedback therapy has been used successfuly by many men and women for the past thirty years, and the 1992 & 1996 AHCPR (Agency for Health Care Policy and Research) Guideline on Urinary Incontinence listed biofeedback as a useful treatment option for reducing the symptoms of incontinence. More recently pelvic floor biofeedback therapy, along with pelvic floor muscle massage and "trigger point release" therapy, have been found to be helpful in men and women with chronic pelvic pain. Monterey Bay Urology Associates employ a pelvic therapy clinician, Kathy Cliff, who specializes in pelvic floor therapy in men and women. We have had excellent results with this type of treatment in patients with bothersome urinary incontinence and pelvic pain.(More)

Sunday 7 November 2010

Movember Updates

Prostate Cancer increase life expectancy?

Interesting article relating to German researchers and highlighted on 'The "New" Prostate Cancer InfoLink' website:

Could having a diagnosis of localized prostate cancer increase life expectancy?

Posted on November 5, 2010

In what can only be described as an unexpected finding, a group of German researchers have documented a greater life expectancy for men diagnosed with early stage prostate cancer than for the male population in general, based on data from the Regensburg cancer registry!
Klotz et al. used epidemiological data from the Regensburg cancer registry to study the survival of patients diagnosed with organ-confined prostate cancer (T1-2N0M0) compared to the standardized age-adjusted survival of the normal male population.

Their analysis is based on data from 4,124 patients with prostate cancer diagnosed between 1998 and 2007, of whom 2,087 men had been diagnosed with localized disease. Here is what they claim to have been able to find:

•At 8 years after diagnosis, patients with T1-2N0Mo prostate cancer had a roughly 10 percent relative increase in survival compared with the normal male population.
•This relative increase in survival could be documented just 3 years after diagnosis.
What could possibly account for such a finding?

It can’t be explained by prostate cancer treatment, because any survival benefit from treatment takes at least 8 to 10 years and maybe longer (based on data from the ERSPC trial). The immediate implication is that (at least in Regensburg) men who have PSA tests (and therefore greater likelihood for a diagnosis of prostate cancer) may have better overall health status than men who do not.

This is not an entirely unreasonable suggestion. There is a well-understood phenomenon that associates positive health-related (“health-seeking”) behaviors with all sorts of other factors. Elsewhere on this site, we discuss the fact that although men who have vasectomies seem to be at greater risk for prostate cancer than men who do not have vasectomies, this is not because they have the vasectomies. Rather, it is because they exhibit such “health-seeking” behavior.

We suspect that in Regensburg (and potentially in many other places) having a PSA test is closely correlated with having regular health checks. Men who have regular health checks arguably may have a superior life expectancy to those who see doctor only when they absolutely have to (although such a benefit has never actually been documented, as far as we know). The other issue that then comes into play is whether men of higher income and/or better education are more likely to have regular health checks than those less fortunate. The authors refer to this in their paper as the relationship between PSA testing and a “socal gradient.”

Could having a diagnosis of localized prostate cancer increase life expectancy?

Monday 1 November 2010

It's Movember!



Mediwatch-OEM Partnership with ACON Laboratories

1 November 2010

Mediwatch plc

OEM Partnership with ACON Laboratories

Mediwatch Plc ("Mediwatch" or "the Company", AIM: MDW), the innovative urological diagnostic manufacturing company, has entered into an Original Equipment Manufacture ("OEM") partnership with ACON Laboratories Inc. ("ACON") to distribute urinalysis products.

This partnership includes a distribution agreement that was signed by Mediwatch to distribute worldwide the ACON line of urinalysis products under the Mediwatch brand, Urinewatch. The worldwide urinalysis market is estimated to be worth over $500 million in annual sales.

ACON is an internationally renowned diagnostic company with manufacturing and distribution in China and the US. This company has been a leader in the production of quality diagnostic tests in their particular field.

Mediwatch is excited to have the opportunity of working with this international group and to add this new diagnostic product to its exclusive urology diagnostic range.

Philip Stimpson, Mediwatch's Chief Executive commented:

"This is an excellent opportunity for Mediwatch to expand its one-stop shop offering for Urologists."

OEM Partnership with ACON Laboratories



FUTURE EVENTS AND LATEST NEWS(Updated 2nd Nov)





Latest News/Website Updates

Director's Shareholding 2nd November

OEM Partnership with ACON Laboratories 1st November



Mediwatch Positions/Jobs



Mediwatch Training Courses

Mediwatch USA- Basic Urodynamics Clinicians’ Workshop 13th-14th November 2010



Future Events

Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later

British Association of Urological Nurses Annual Conference and Exhibition UK 4th-5th November 2010 Mediwatch are Exhibiting

28th Biennial Congress of the Urological Association of South African South Africa 16th-19th November 2010 Mediwatch distributor 'Tecmed Africa'are Exhibiting

19th Malaysian Urological Conference Malaysia-25th-28th November 2010


STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...


Website Update (Aug)-Mobile Watch

Interim Results

Mediwatch Newsletter-July 2010 Edition

OEM Partnership with Thought Technology Ltd Mediwatch-14th June

Distribution Agreement with GE Healthcare Mediwatch-8th June

Director Shareholding 4th May

Director Shareholding 14th April


Mediwatch Annual Report 2009


December/January Mediwatch Newsletter

Mediwatch Interim Results for the six month ended 30 April 2009

Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009

Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009


Tuesday 26 October 2010

Gala dinner raises £10,000 for Surrey urology services

23 October 2010

Nearly £10,000 has been raised to advance the diagnosis, treatment and management of prostate cancer and other urological conditions in Surrey.

The money was raised at a gala dinner held at Wentworth Golf Club, in Virginia Water, in aid of Ashford and St Peter's Hospitals NHS Trust.

The event was part of the new Golf Marathon charity initiative, aiming to raise £1m to fund new services.

Funds were also raised by golfers playing a sponsored round of golf.


The Golf Marathon event was supported by comedian Ronnie Corbett

The gala dinner was attended by comedian Ronnie Corbett, who provided the entertainment.

'Important message'

After dinner auction prizes included donated gifts from David Beckham, John Terry, Nick Faldo and Sam Torrance as well as rounds of golf with various celebrities including Corbett, Tom O'Connor and Jodie Kidd.

The Golf Marathon aims to support several new services at Ashford and St Peter's hospitals, including a laser to treat kidney stones and certain types of kidney cancer.

Justin Collins, urology consultant, said: "We wanted to work with local golf clubs because of the demographics and the fact that most members of a club will know someone with a urological problem.

"Also, they are great socialising networks and a good way to spread an important message about how urological diseases, such as prostate cancer, kidney stones and bladder cancer affect so many people."

Gala dinner raises £10,000 for Surrey urology services

NEWS-Week Ending 31st October(Updated-2 Posts)

Health board looking at privatising urology work New Zealand-28th October

$1 Million Fundraising Goal For Prostate Cancer Set By Movember Edmonton Canada-26th October

Thursday 21 October 2010

October-The Music,Film and Odd Joke spot


Los Pistoleros - Swinging with The Chickens













Wednesday 20 October 2010

Mediwatch Product Update-Biofeedback (Venus Clinic)

This system is only available in the USA at the present time and a 'data sheet' has now been added to the Mediwatch website:

Thursday 14 October 2010

Urine-based test for a protein called MSMB

If you just read the media reports (for example, from Reuters, from the BBC or from The Daily Telegraph) you might get the idea that a new urine-based test for a protein called MSMB is vastly better at detecting prostate cancer than the PSA test. Sorry, but that is not actually the case at all.
To get an accurate understanding, you need to look at the full text of the actual article by Whitaker et al. in the on-line journal PLoS One.

What Ms. Whitaker and her colleagues have shown is that in men who carry a specific gene (the risk allele rs10993994), a protein known as microseminoprotein-β (MSMB) is significantly less likely to be found in the urine of men who have prostate cancer (or prostate intraepithelial neoplasia [PIN]) than it is in men with only benign prostate tissue. We already knew that the presence of rs10993994 is associated with increased risk for prostate cancer.

Whitaker et al. also were able to show that testing for MSMB in urine is a better indicator for prostate cancer risk than testing for prostate-specific antigen (PSA) in urine, but it is not better than testing for PSA in serum (the normal method of testing for PSA). And there is some evidence that the concentration of MSMB in urine may be associated with the Gleason score of a cancer in an individual patient who expresses the rs10993994 risk allele.

It is also important to understand, however, that Kader et al. have already shown that once prostate cancer tumors have developed, expression of rs10993994 has little effect on disease progression. The implication is that any increase in risk associated with expression of rs10993994 and MSMB affects the benign prostate gland and only the initial stages of tumor development

Let us be very clear. This is an interesting scientific finding. It demonstrates that there is the potential to link genetic signals of risk for prostate cancer to clinical signals of risk (expression or non-expression of a specific protein). It would also allow us to combine data on the presence/absence of MSMB in urine with data from other tests to assess risk for prostate cancer in particular individuals. Most specifically, it would theoretically help to be able to identify a subset of men who are at risk for prostate cancer long before there might be any evidence of disease based on a biopsy. However, even if everything were to go well, it may take 5 or more years to gain regulatory approval for such a test, and we would need additional information about it’s accuracy. Some initial testing on actual patients has already been initiated at one of the major UK prostate cancer clinical research centers.

Link to above article:

Is MSMB the next great thing in prostate cancer testing?


and from the UK Prostate Cancer Charity:

The Prostate Cancer Charity comments on new research into the MSMB protein as a potential marker for prostate cancer

The Prostate Cancer Charity comments on new research published in PLoS ONE, which suggests that microseminoprotein-beta (MSMB), a common protein found in semen, could provide an indication of a man’s risk of developing prostate cancer.

Dr Kate Holmes, Research Manager at The Prostate Cancer Charity, explains: “These preliminary results show that MSMB, a protein produced by the prostate gland, is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease. The study also found that men with an aggressive tumour were also likely to have lower levels of the protein in their urine.”

She continued: “The study suggests that measuring levels of this protein could potentially be a powerful way to predict how likely a man is to develop prostate cancer. However, further research on a much larger scale is needed to determine how effective the detection of MSMB in the urine is for predicting the risk of, and potentially even diagnosing, prostate cancer.

“Given the known limitations of the PSA blood test, finding a technique to accurately diagnose prostate cancer is the Holy Grail of research into the disease, which is why these results are potentially exciting. More needs to be understood about MSMB, such as whether it is linked to non-cancerous prostate diseases. Once we have more information, we can better evaluate whether detecting levels of MSMB has a useful role in diagnosing prostate cancer. An accurate, reliable urine test for prostate cancer would be an invaluable tool if it is proven to be successful on a large scale.”

Monday 11 October 2010

Abiraterone

This has nothing to do with Mediwatch but of interest all the same.

"11 October 2010

The Prostate Cancer Charity comments on latest research into abiraterone
The Prostate Cancer Charity comments on the interim results of a phase III trial into the prostate cancer drug abiraterone, which has been shown to extend the lives of men living with advanced disease by an average of almost four months.

John Neate, Chief Executive at The Prostate Cancer Charity, explains: “These initial findings are particularly important as they offer new hope to men diagnosed with an advanced form of prostate cancer who can quickly run out of treatment options once their tumour stops responding to the existing methods of controlling its progression.

“The results of the trial conducted in over 1,000 men across 13 countries, indicate that abiraterone is able to prolong the lives of men living with the most advanced stages of the disease by an average of almost four months. What is particularly encouraging is that men taking the drug did not generally experience significant side effects, such as those normally associated with chemotherapy treatment.”

He continued: “Abiraterone represents a significant move forward in the treatment of advanced prostate cancer for some time. To date, the full results of this study are yet to be published and reviewed. We look forward to seeing these results and hope that they will provide the robust evidence necessary for abiraterone to be licensed and made generally available on the NHS to all men who need it.”"



*************************************************************************************

"Abiraterone acetate extends median survival by 3.9 months in mCRPC

Posted on October 11, 2010 by Sitemaster

The results of a randomized, double-blind, placebo-controlled, multi-center, Phase III clinical trial comparing abiraterone actetate + prednisone to a placebo + prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) were presented today at the annual meeting of the European Society for Medical Oncology in Milan, Italy.

This first Phase III trial of abiraterone acetate, initiated in early 2008, enrolled 1,195 men with mCRPC who had progressive prostate cancer following one or two courses of chemotherapy, including one course of docetaxel-based chemotherapy.

Patients could not have received prior treatment with ketoconazole, abiraterone acetate, any other drug that acts as a CYP17 inhibitor, or any other investigational drug that targets the androgen receptor. They also had to have an ECOG performance status of 0 to 2. Eligible patients were enrolled at 147 clinical sites in Australia, Europe, the USA, and Canada.

The key data presented by Dr. de Bono on behalf of the investigators are as follows:

•Patients were randomized in a 2:1 fashion, with 797 patients randomized to abiraterone acetate + prednisone and 398 patients randomized to a placebo + prednisone.
•Patients treated with abiraterone + prednisone had a 35 percent reduction in their risk of death (hazard ratio [HR] = 0.65) compared to those receiving a placebo + prednisone.
•Median survival of patients receiving abiraterone was 14.8 months compared to 10.9 months for those receiving the placebo.
•Time to disease progression was 10.2 months among those on abiraterone and 6.6 months for the placebo patients.
•The two most evident adverse effects of abiraterone acetate + prednisone were fluid retention and hypokalemia (elevated potassium levels).
•Most adverse events of abiraterone acetate + prednisone appear to be manageable and do not include any of the classic side effects of chemotherapy.
Marketing applications for abiraterone in the U.S. and Europe are scheduled to be filed by the end of this year. Additional details about the results of the trial are available in a media release from subsidiaries of Johnson & Johnson.

Abiraterone acetate becomes the second drug this year to demonstrate a clear median survival benefit in men with mCRPC and with progressive disease after treatment with docetaxel-based chemotherapy, representing a practice-changing advance in the management of late-stage prostate cancer."

The "New" Prostate Cancer InfoLink

Wednesday 6 October 2010

FUTURE EVENTS AND LATEST NEWS(Updated 11th October)





Latest News/Website Updates

Growing Companies Investor Days 2010 UK-Birmingham, 14 October 2010

Director's Shareholding 6th October 2010

Director's Shareholding 5th October 2010

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1st October 2010

Trading Update 1st October 2010






Mediwatch Positions/Jobs



Mediwatch Training Courses


Future Events

Events where Mediwatch are attending/exhibiting will be marked as so or updated,hopefully before the event is finished.More Events to add later

AUA-North Central Section 84th Annual Meeting (Chicago 29th September-2nd October) Mediwatch are Exhibiting

108th Annual Meeting of the New York Section of the AUA (Poland 3rd-9th October)

SUNA 41st Annual Conference (USA-Boston 8th-11th October)Mediwatch are Exhibiting

Clinical Advances In Male Urology (UK-London 11th-12th October)

Congreso Argentino De Urología 2010 (12th-15th October)

2010 SIU World Meeting (Marrakech 13th-15th October)

83° Congresso SIU: MILANO 2010 (Italy 17th-20th October)

STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...


Website Update (Aug)-Mobile Watch

Interim Results

Mediwatch Newsletter-July 2010 Edition

OEM Partnership with Thought Technology Ltd Mediwatch-14th June

Distribution Agreement with GE Healthcare Mediwatch-8th June

Director Shareholding 4th May

Director Shareholding 14th April


Mediwatch Annual Report 2009


December/January Mediwatch Newsletter

Mediwatch Interim Results for the six month ended 30 April 2009

Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009

Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009


Tuesday 28 September 2010

The prostate cancer screening controversy: an evolving, risk-based perspective

The link below takes you to 'The "New" Prostate Cancer InfoLink' website and an article posted on 25th September 2010.

Yes,it's the old issue of PSA testing but with the replies makes for interesting reading so thought I'd highlight it here:

The prostate cancer screening controversy: an evolving, risk-based perspective

Saturday 25 September 2010

Mediwatch Distributors-Iran

Forgot to follow this up Mediwatch Distributors-Iran from June 2010.

Tajhiz Gostaresh Sina

Anyway,after further checks I've added Tajhiz Gostaresh Sina to the Mediwatch distributors list found in the main section of April 2009 under Distributors for Mediwatch Products

Friday 24 September 2010

Blue September

Sorry,a bit late but will add to page.











Wednesday 22 September 2010

Mediwatch Distributor Update-Vingmed

Vingmed have updated there website (Not sure when) with PSAwatch and classing it as a new offering:

PSAwatch

Mediwatch Distributor-Medical Shop (Serbia)

'Medical Shop' have now updated or it may even be a new website to include mediwatch products.

Medical Shop was formed in 1993. with the primary goal to supply University Clinics, Medical Centers, Hospitals with medical equipment and supplies.



I will add this company to the main section found within April 2009 under Distributors for Mediwatch Products

Tuesday 21 September 2010

Unite ByCycling-The Prostate Cancer Charity Tour Ride

Sporting stars among those getting on their bikes in Stoke-on-Trent for The Prostate Cancer Charity Tour Ride

21 September 2010

Sporting legends Mark Bright and Gladstone Small, better known for football and cricket respectively, are saddling up for a challenge of a different kind, in aid of The Prostate Cancer Charity.

The footballer-turned pundit and former England and Warwickshire fast bowler are joining more than 1,500 riders heading to Stoke-on-Trent this weekend and taking to two wheels in the Charity’s Tour Ride event.

Sporting stars among those getting on their bikes in Stoke-on-Trent for The Prostate Cancer Charity Tour Ride





Celebrities and cyclists get in the saddle for The Prostate Cancer Charity Tour Ride

20 September 2010

"A host of famous faces put the final stage of The Tour of Britain to the test today, joining almost 1,000 amateur cyclists in The Prostate Cancer Charity Tour Ride in London ahead of the professional race."

"The sportive was one of three events the Charity is staging across the UK, this September, as part of its ‘Unite ByCycling’ initiative, which aims to raise awareness of prostate cancer, the most common cancer in men in the UK, as well as to raise funds to fight the disease. In addition to the London Ride, 1,500 people saddled up for the South West Ride on Sunday 5 September and people still have the opportunity to take to two wheels in the Stoke-on-Trent ride on Sunday 26 September. To find out more visit http://www.tourride.co.uk/

Celebrities and cyclists get in the saddle for The Prostate Cancer Charity Tour Ride

Ken Hom speaks publicly of prostate cancer

Ken Hom has been treated for prostate cancer following a shock diagnosis, he has revealed.


16 September 2010

The world renowned chef, regarded as the final word in Chinese cuisine, decided to speak out about his journey with the disease in a bid to ensure other men become more vigilant and act upon any concerns.

Hom, well-known in the UK following a series of respected BBC cookery programmes and a number of best-selling cookbooks, was diagnosed in mid-March this year following a routine annual check up in Thailand, where he spends much of the year. The results of a PSA blood test, commonly used to detect a problem with the prostate, were much higher than the year before. When a further test two weeks later revealed an even higher score, Ken’s doctor ordered an immediate biopsy.



Ken’s cancer was an aggressive form of the disease, but luckily contained within the prostate gland.

He said: “My initial reaction was one of shock. No one wants to find out they have a time-bomb in their body. I swim almost daily, eat a healthy diet, drink lots of green tea and had no symptoms – cancer was the last thing on my mind.”

Ken, like all men diagnosed with prostate cancer, faced a difficult decision over which treatment option would be best for him. Ultimately, he opted to have Proton*, a course of radiotherapy treatment, in southern Japan, undergoing 37 sessions in two months - with his partner at his side all the way. His close circle of friends emailed him constantly with messages of support.

Ken said: “I chose Japan because my Japanese doctor was able to get me immediately into the Proton programme. I was lucky. I had treatment choices because they caught the cancer early, but another year on it may well have been too late. Every man thinks cancer can’t happen to me, but it can, and we all need to have regular health checks and realise how serious this disease can be.”

Luckily Ken emerged from the treatment, which can cause urinary and bowel problems, without side effects, although he will need to have a PSA test every three months for the next ten years to track his progress. If anything, Ken’s journey with prostate cancer has reinforced his Zen attitude and the positivity that goes with it.

The 61-year-old chef, who lives between Paris and Bangkok, is determined to speak out publicly and ensure other men become more aware of the disease. Prostate cancer is a complex disease, and similarly to Ken, many men will not display any of the symptoms, such as urinating more frequently in the night, a weak or reduced urine flow, or a feeling that the bladder has not emptied properly, which can all be indicators of the disease.

“I have chosen to speak out about my experiences of prostate cancer to try and help other men be less afraid if they are diagnosed and to seek help as soon as possible. It is terribly important to catch aggressive prostate cancer early. All men need to know that prostate cancer exists. Let’s not walk around with blindfolds on and let machoism be the death of us,” he urged.

Speaking about Ken’s diagnosis, John Neate, Chief Executive of The Prostate Cancer Charity, explains: “We are hugely grateful to Ken for taking the brave decision to speak out about his own diagnosis of prostate cancer and we hope that his experience will inspire many men to start thinking about the disease and whether they may be at risk too. Although prostate cancer is more common in men over 50, it is vital that all men take control of their health and find out about the facts. We encourage any man who may be concerned about any aspect of prostate cancer to visit their GP.”

*Proton is a radiotherapy treatment, not currently available in the UK. Further information is available on request.

AUA Champions New Prostate Legislation Introduced In Senate

Article Date: 21 Sep 2010 - 3:00 PDT

The American Urological Association (AUA) is pleased to announce its support for S. 3775, the Prostate Research, Outreach, Screening, Testing, Access and Treatment Effectiveness (PROSTATE) Act of 2010, introduced this week by Senators Jon Tester (D-MT) and George Voinovich (R-OH). Representative Edolphus Towns (D-NY-10) is expected to introduce companion legislation in the House in the coming days. The AUA worked closely with the Senate to assist in the development of this critical legislation.

Prostate cancer is the second-leading cause of cancer death in men, and more than 210,000 are expected to be diagnosed with the disease in 2010. There are significant racial disparities in regard to prostate cancer: African American men are not only more likely to develop the disease, but are also more than twice as likely to die from it.

Significant national resources are focused on prostate cancer, but the disparate research and healthcare programs across federal agencies should be coordinated to improve accountability and actively encourage the translation of research into practice and to identify and implement best practices. The PROSTATE Act would help foster an integrated and coordinated focus on effective prevention, diagnosis and treatment of this disease.

Specifics of the bill include:

- The formation of an Interagency Prostate Cancer Coordination and Education Task Force composed of agencies from the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DoD) and led by the U.S. Department of Veterans Affairs (VA), which will identify and catalog prostate cancer activities across these agencies; develop a strategy to improve the research portfolio; eliminate duplication between agencies; identify best practices; expand collaboration; increase patient and medical community participation; and develop a coordinated message related to screening and treatment for prostate cancer.

- Require the VA, DoD and HHS to coordinate and intensify prostate cancer research, including improvements or alternatives to the prostate-specific antigen (PSA) test and additional tests to distinguish indolent from aggressive disease; advance the understanding of the etiology of the disease; establish clinical registries for prostate cancer; and assess appropriate imaging modalities.

- Establish a grant program to build upon existing knowledge gained from comparative effectiveness research, and recognize and address the racial and ethnic disparities in the incidence and mortality rates of prostate cancer.

-Establish four-year telehealth pilot projects in a variety of geographic areas, including rural, that contain high proportions of medically underserved populations. Such projects will promote efficient use of specialist care through better coordination of primary care and physician extender teams in underserved areas and more effectively employ tumor boards to better counsel patients.

- Require the development of a national education campaign intended to encourage men to seek prostate cancer screening when appropriate. The national campaign shall ensure materials are readily available in communities with racial disparities in the incidence and mortality of prostate cancer.

"Prostate cancer is the second leading cause of cancer death in American men. One in six men will be diagnosed in his lifetime - and more than 210,000 men will be diagnosed this year alone," said Datta Wagle, MD, president of the AUA. "We extend our thanks to Senators Tester and Voinovich for taking a leading role in combating prostate cancer by introducing this legislation."

Source:
American Urological Association

AUA Champions New Prostate Legislation Introduced In Senate

and the AUA link:

AUA-September 17, 2010

NEWS-Week Ending 26th September (Updated-2 posts)

Libby, Montana - Blue Faced and Big Hearted USA-23rd September

Prostate Cancer: Not Just an Old Man's Cancer USA-22nd September

Sunday 19 September 2010

East Lancashire specialists offer help-Incontinence

10:46am Friday 17th September 2010

By Neil Docking »
Reporter


INCONTINENCE specialists at East Lancashire Hospitals have reminded people not to suffer in silence.

One in five adults suffer from incontinence, and this week a Royal College of Physicians audit of services claimed millions of people in the UK with bladder and bowel problems face a ‘life sentence’ of suffering because of poor care.

However, the hospitals trust is adamant that is not the case in East Lancashire, where a dedicated team assesses bladder problems.

The team includes consultant gynaecologists and urologists, specialist physiotherapists, specialist gynaecology and urology nurses, a specialist midwife and community continence nurse advisers.



Simon Hill, consultant urogynaecologist, said their work was vital to restoring people’s self-esteem.

He said: “I am really proud of the service.

“Incontinence isn’t a sexy subject, because you can’t die from incontinence. But you can die from embarrassment.

“It can affect people’s lives in every way, from their work life, to their home life, to their sex life.”

Mary Hill is an advanced physiotherapist in women’s health and continence with 30 years’ experience.

She said a lot of women were referred to her and fellow physiotherapist Sally Broadhurst from the hospital’s perineal clinic, led by specialist midwife Annette Dugdale.

It looks after new mothers who have experienced difficulties during pregnancy, such as tears, leading to pelvic floor muscle dysfunction.

Patients are taught pelvic floor muscle-strengthening exercises that can be carried out independently.

They are then reassessed as often as needed.

Mary said: “Continence problems are very distressing, but the majority of the time they can be improved and sometimes cured.

“With the right attention you can improve someone's quality of life."

Wednesday 15 September 2010

An important week for prostate cancer in Washington, DC

Taken from the "The "New" Prostate Cancer InfoLink":

Over the next few days, hundreds of prostate cancer patients, advocates, and researchers will be gathering in DC for a series of events focused on progress against prostate cancer. And there is a shared five-point plan of action to take to Congress and the White House.

Starting today the “Advance on Washington” initiative will feature a series of events coordinated by the Prostate Cancer Foundation, the Prostate Health Education Network, ZERO — The Project to End Prostate Cancer, and others.

Specific events that will occur during the week include:

•The Prostate Cancer Foundation’s Scientific Retreat, at the Washington Hilton (on September 14-16)

•The ZERO Prostate Cancer Summit, at the L’Enfant Plaza Hotel (on September 14-16)

•The Prostate Health Education Network’s African American Prostate Cancer Disparity Summit at the Congressional Black Caucus Meeting (on September 16-17)

•The Black Barbershop Health Outreach Program’s Prostate Education Program at select barbershops throughout the Washington, DC and Baltimore metro areas (on September 18)

An additional feature is the announcement of a new five-point call to action for policy-makers in Washington issued by the Prostate Cancer Foundation and supported by most of America’s Prostate Cancer Organizations (including Prostate Cancer International).

The complete five-point plan can be seen if you click here, together with the accompanying letter to President Obama and members of Congress. However, the five key points are as follows:

1.Increase the National Cancer Institute’s $5 billion annual budget to accelerate basic and treatment sciences research for human prostate cancer from $294 million to a transparent $400 million.

2.Increase the appropriation for the Congressionally Directed Medical Research Program for Prostate Cancer at the Department of Defense to $120 million from $80 million.

3.Establish an Office on Men’s Health (OMH) in the Department of Health and Human Services equivalent to The Office on Women’s Health (OWH) established in 1991.

4.Create a Prostate Cancer Scientific Advisory Board for the Office of the Chief Scientist at the U.S. Food and Drug Administration to accelerate real-time sharing of the latest research data and accelerate movement of new medicines to patients.

5.Create human capital by launching more careers of the best and brightest scientists in the U.S. to solve the prostate cancer problem.

Call or write to President Obama and your Congressional representatives and ask them to support this five-point plan. We are beginning to make serious progress against prostate cancer, and the next decade could be crucial to our ability to seriously impact the effect of this form of cancer on men the world over.

We had asked the President to light the White House blue and/or feature a blue ribbon in celebration of Prostate Cancer Awareness Month during this week — no sign of that yet (that we have heard about), but there are still another few days in the week!

An important week for prostate cancer in Washington, DC

NEWS-Week Ending 19th September (Updated 2 Posts)

Prostate Cancer Awareness Week begins Monday" Canada-19th September

Single prostate cancer test could save tens of thousands of lives UK-15th September

Friday 10 September 2010

This Fall 2010 issue of QUEST

'QUEST' is a publication by Dr. Catalona and the Urological Research Foundation.

'Please note that all QUEST material is under copyright and cannot be duplicated for any reason other than personal use.'

I'll remove this post if classed as being 'duplicated'




And a link to 'Dr. Catalona and the Urological Research Foundation' main website which i think can be found under the month of April 2009

The Prostate Cancer Charity comments .........

10 September 2010

The Prostate Cancer Charity comments on new research which suggests that men at a higher genetic risk of prostate cancer could benefit from screening for the disease

The Prostate Cancer Charity comments on new preliminary research published today (10 September 2010) in the British Journal of Urology International which suggest that men at a higher genetic risk of developing prostate cancer could benefit from regular screening for the disease using the PSA blood test.

John Neate, Chief Executive of The Prostate Cancer Charity, explains: “These preliminary findings show that it may be beneficial to use the PSA blood test to regularly screen men at higher risk of prostate cancer because of known faults in a BRCA1 or BRCA2 gene.

“The PSA test, which is the first step along the journey to prostate cancer diagnosis, is far from perfect and can lead to over-diagnosis and unnecessary treatment in some men with a slow-growing form of the disease. However, this study suggests that a targeted approach to specifically screening men thought to be at a higher genetic risk of developing the disease may, overall, do more good than harm.

“These results are early, initial results from a study which will take many years to complete. We await with interest the full results of this study and we urge the UK National Screening Committee, the body responsible for assessing the validity of the PSA blood test as a screening tool, to consider the research findings once the study is complete. In the meantime, it is imperative that we move quickly to a position of ‘universal informed choice’ where all men - particularly those over 50 or at increased risk of the disease - have the opportunity to make an informed decision about whether to have the PSA test.

"We encourage any men who may be concerned about any aspect of prostate cancer to visit their GP,” he added.

ENDS